How Does Treatment Coverage and Proportion Never Treated Influence the Success of Schistosoma mansoni Elimination as a Public Health Problem by 2030?

Klodeta Kura*, Nyamai Mutono, Maria Gloria Basáñez, Benjamin S. Collyer, Luc E. Coffeng, S. M. Thumbi, Roy M. Anderson

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
5 Downloads (Pure)

Abstract

Background: 

The 2030 target for schistosomiasis is elimination as a public health problem (EPHP), achieved when the prevalence of heavy-intensity infection among school-Aged children (SAC) reduces to <1%. To achieve this, the new World Health Organization guidelines recommend a broader target of population to include pre-SAC and adults. However, the probability of achieving EPHP should be expected to depend on patterns in repeated uptake of mass drug administration by individuals. 

Methods: 

We employed 2 individual-based stochastic models to evaluate the impact of school-based and community-wide treatment and calculated the number of rounds required to achieve EPHP for Schistosoma mansoni by considering various levels of the population never treated (NT). We also considered 2 age-intensity profiles, corresponding to a low and high burden of infection in adults. 

Results: 

The number of rounds needed to achieve this target depends on the baseline prevalence and the coverage used. For low-and moderate-Transmission areas, EPHP can be achieved within 7 years if NT ≤10% and NT <5%, respectively. In high-Transmission areas, community-wide treatment with NT <1% is required to achieve EPHP. 

Conclusions: 

The higher the intensity of transmission, and the lower the treatment coverage, the lower the acceptable value of NT becomes. Using more efficacious treatment regimens would permit NT values to be marginally higher. A balance between target treatment coverage and NT values may be an adequate treatment strategy depending on the epidemiological setting, but striving to increase coverage and/or minimize NT can shorten program duration.

Original languageEnglish
Pages (from-to)S126-S130
JournalClinical Infectious Diseases
Volume78
Issue numberSupplement_2
DOIs
Publication statusPublished - 15 May 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Fingerprint

Dive into the research topics of 'How Does Treatment Coverage and Proportion Never Treated Influence the Success of Schistosoma mansoni Elimination as a Public Health Problem by 2030?'. Together they form a unique fingerprint.

Cite this